Moreover, investigations into intrinsic resistance mechanisms at immune checkpoint blockade (ICB) sites through comprehensive single-cell profiling of melanoma have shown that targeting transcription factor 4 (TCF4) expression increases sensitivity to ICBs and targeted therapies[16]. Here, TCF4 is linked to melanoma.